3 “Perfect 10” Stocks Insiders Are Snapping Up

 | Aug 12, 2021 08:09AM ET

One strategy for selecting top stocks is to track insider transactions. After all, if insiders are dipping into their own pockets you can imagine it’s because they believe the stock looks compelling. A Harvard study revealed that insider purchases earn “abnormal” returns of more than 6% per year. The authors of the study conclude that insider buyers “have a good feel for near-term developments within their firm.”

The advantage of following these insiders isn’t just that they are privy to data which the rest of us don’t necessarily know – it’s also that they are held responsible for their decisions. Company officers can’t just make trading choices based on personal preference or profit. They must account for their choices to board members and shareholders – and that audience wants to make money, too. So, when corporate insiders start buying up stock in their own company, it’s a strong signal for investors.

Bearing this in mind, we used the platform to point us in the direction of three “Perfect 10” stocks the insiders are snapping up. The platform gives every stock a single-digit score, based on a summing up from 6 separate factors. The factors used are known to correlate with future overperformance; when they align together it’s a strong indication for buyers to consider. Let’s take a closer look.

Bright Health Group ( )

We’ll start in the health insurance industry, where Bright Health Group (NYSE:BHG) takes a different approach to health care coverage. Instead of focusing on the needs of large corporations and major providers, the company aims to take a ‘consumer centric’ approach to health insurance, matching policies to the needs of the end user. Since its founding in 2016, the Minnesota-based insurance provider grown rapidly, and now claims over 660,000 policy-holding customers.

The biggest news items from Bright in recent months have been the company’s IPO and its 2Q21 earnings report. The IPO was held at the end of June, and Bright put 51.35 million shares of common stock on the public market, with an initial price of $18 each. This was lower than the original target range of $20 to $23 per share, and the offering brought in over $924 million in new capital.

In the Q2 report, Bright’s first as a publicly traded entity, the company reported GAAP revenues of $1.11 billion, a 275% gain from the year-ago quarter. The revenue gain was driven by an equally impressive gain in membership of the course of the year; from 2Q20 to 2Q21, Bright’s membership grew 220%, from 207K to more than 662K. In addition to the organic revenue gain, Bright also saw a one-time increase in investment income, or $58.5 million from unrealized equity security gains.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Turning to the insiders, two members of Bright’s Board of Directors have recently made major purchases, pushing the insiders sentiment strongly positive. Manuel Kadre bought 50,000 shares, spending $432,500 for them. And Jeffery Immelt, best known as the former CEO of General Electric (NYSE:GE), bought 114,000 shares for just over $1 million.

BHG has also caught the attention of RBC’s 5-star analyst Frank Morgan, who wrote after the recent earnings release: “We found nothing in the second quarter that would derail our investment thesis… Bright Health Group posted solid 2Q21 results, which as expected, reflect strong IFP membership growth and favorable operating cost development on increased scale. Adjusted EBITDA, while still a deficit, was favorable to consensus, though we should note that quarterly seasonality assumptions varied significantly heading into the print. Consensus was stronger around full year-revenue, which is bracketed by management’s initial guidance, with MCR also falling in line…”

In line with these comments, Bright rates BHG shares an Outperform (i.e. Buy), along with a $22 price target. Should his thesis play out, a potential upside of ~161% could be in the cards.

Overall, 9 analysts have reviewed BHG since its IPO, and of them, 7 recommend a Buy against 2 Holds, setting up the Strong Buy consensus rating. The shares are priced at $8.44 and their $20.11 average price target suggests ~138% upside in the next 12 months. (See BHG stock analysis )